Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI)
Stock · NASDAQ · Health Care
$6.81as of 10/16/2026
Price chart
Active signals
MRVI Signal Track Record
How signals performed across all stocks →What MRVI's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 39 | -2.3% | 41% | August 26, 2026 |
| Bollinger Band Breakdown | 25 | +6.7% | 64% | August 11, 2026 |
| Bollinger Band Breakout | 23 | -10.9% | 35% | October 5, 2026 |
| 200-Day Moving Average TouchActive now | 8 | +18.5% | 63% | April 10, 2026 |
| Any 20-session window (baseline) | -2.0% | 46% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About MRVI
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields o…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 415
- Website
- www.maravai.com/
Fundamentals
- 1-day range
- $6.87$7.07
- Market cap
- $1.61B
- P/E (trailing)
- —
- P/E (forward)
- -68.70
- EPS (trailing)
- $-0.53
- Dividend yield
- —
- Beta
- 0.63
- Avg. volume
- 3.19M
How Maravai LifeSciences Holdings Inc. Class A Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
6 analyst ratings
Maravai LifeSciences Holdings Inc. Class A Common Stock Competitors
Chosen by industry and closest market cap.
- MRVIMaravai LifeSciences Holdings Inc. Class A Common Stock$6.79▼ 3.96%Market cap $1.61BP/E —$2.55$9.42
- TYRATyra Biosciences Inc. Common Stock$18.52▼ 2.73%Market cap $1.61BP/E —$12.96$40.65
- ANABAnaptysBio Inc. Common Stock$46.61▼ 4.31%Market cap $1.62BP/E 7.14$20.18$72.36
- AAPGAscentage Pharma Group International American Depository Shares$15.37▲ 4.63%Market cap $1.60BP/E —$27.12$75.1
- TRAXFirst Tracks Biotherapeutics Inc. Ordinary Shares$34.46▼ 4.38%Market cap $1.58BP/E —$14.72$49.91
- INVAInnoviva Inc. Common Stock$20.78▼ 0.38%Market cap $1.56BP/E 4.25$16.52$25.15
- ZYMEZymeworks Inc. Common Stock$25.03▼ 2.80%Market cap $1.69BP/E —$16$31.34
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| MRVI Maravai LifeSciences Holdings Inc. Class A Common Stock | $1.61B | — | $6.79 | ▼ 3.96% | $2.55$9.42 |
| TYRA Tyra Biosciences Inc. Common Stock | $1.61B | — | $18.52 | ▼ 2.73% | $12.96$40.65 |
| ANAB AnaptysBio Inc. Common Stock | $1.62B | 7.14 | $46.61 | ▼ 4.31% | $20.18$72.36 |
| AAPG Ascentage Pharma Group International American Depository Shares | $1.60B | — | $15.37 | ▲ 4.63% | $27.12$75.1 |
| TRAX First Tracks Biotherapeutics Inc. Ordinary Shares | $1.58B | — | $34.46 | ▼ 4.38% | $14.72$49.91 |
| INVA Innoviva Inc. Common Stock | $1.56B | 4.25 | $20.78 | ▼ 0.38% | $16.52$25.15 |
| ZYME Zymeworks Inc. Common Stock | $1.69B | — | $25.03 | ▼ 2.80% | $16$31.34 |
P/E shows — for peers not currently carrying a live signal of their own.
Insider Activity
Insider Actions →- Brust Bernd · August 10, 2026 · Tax Withholding29.3K @ $6.23
- Asarpota Rajesh · July 30, 2026 · Tax Withholding5.5K @ $6.59
- Brust Bernd · July 8, 2026 · Tax Withholding29.3K @ $5.92
- Asarpota Rajesh · June 30, 2026 · Tax Withholding65.6K @ $6.39
- ORESHACK KURT · June 10, 2026 · Sale25.0K @ $5.1
- ORESHACK KURT · June 9, 2026 · Sale25.0K @ $5.06
- Gregory T. Lucier · June 9, 2026 · Gift46.3K
- Brust Bernd · June 8, 2026 · Tax Withholding351.0K @ $5.02
- Gregory T. Lucier · May 26, 2026 · Grant46.3K @ $4.38
- GRAY SUSANNAH · May 26, 2026 · Grant46.3K
- MARKER LUKE JOSEPH · May 26, 2026 · Grant46.3K
- CUNNINGHAM SEAN LAURENCE · May 26, 2026 · Grant46.3K
- DeFord John A · May 26, 2026 · Grant46.3K
- MIHAS CONSTANTINE S · May 26, 2026 · Grant46.3K
- R. Andrew Eckert · May 26, 2026 · Grant46.3K
Institutional Ownership
March 31, 2026
- Total shares held
- 120.01M
- Total value held
- $335.65M
- Institutional holders
- 155
- Unknown20.15M
- Unknown10.24M
- Unknown9.35M
- Unknown7.26M
- Unknown6.31M
- Unknown5.45M
- Unknown4.26M
- Unknown3.50M
- Unknown3.42M
- Unknown3.32M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Maravai LifeSciences Releases Q2 2026 Earnings Call Transcript
Maravai LifeSciences has published the full transcript of its second-quarter 2026 earnings call. This document provides detailed management commentary on recent operational performance and financial results. The release serves as a primary source for investors seeking to understand the company's current strategic direction and outlook.
Maravai LifeSciences Releases Q2 2026 Earnings Call Transcript. Maravai LifeSciences has published the full transcript of its second-quarter 2026 earnings call. This document provides detailed management commentary on recent operational performance and financial results. The release serves as a primary source for investors seeking to understand the company's current strategic direction and outlook.